Skip to main content

Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility

Completed · Not applicable · NCT03641677

Conditions: Lung Diseases

At a glance

Research payments reported, 2025
$73,478
U.S. investigators named
6
Sites paid
5
Planned or actual enrollment
174

About the trial

Sponsor
Lung Bioengineering Inc.
Tested
Centralized Lung Evaluation System (device), Lung Transplant (procedure)
Dates
Started 2019-04-21; completion 2024-01-18
Results posted
Yes

The objective of this study is to evaluate the safety and effectiveness of the Centralized Lung Evaluation System (CLES) in enabling evaluation of potential donor lungs not otherwise used for transplant into subjects with end stage, survival-limiting lung disease in need of lung transplantation. This will be accomplished by evaluating subject survival at the later of 12 months or hospital discharge post-transplant.

From ClinicalTrials.gov, last updated 2026-09-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

United Therapeutics Corporation reported $73,478 in research payments for this study in 2025 (20 payments).

Products named: Steen Solution

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.